| ENTRECTINIB | None | ||
| 100MG, 200MG |
Less Than $1000 mn
|
||
| None | None | ||
| None | None | ||
| None | None | ||
| ROZLYTREK is a kinase inhibitor indicated for the treatment of: • Adult patients with ROS1-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. • Adult and pediatric patients 12 years of age and older with solid tumors that: o have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion as detected by an FDA-approved test without a known acquired resistance mutation, o are metastatic or where surgical resection is likely to result in severe morbidity, and o have progressed following treatment or have no satisfactory alternative therapy. | |||
|
Yes
| |||
| ROZLYTREK | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 | Patent 12 | Patent 13 | Patent 14 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| *** ********* | ||||||||||||||
| *********** ******** *********** ****** ** ****** ********** | *********** ******** *********** ****** ** ****** ********** | *********** ******** *********** ****** ** ****** ********** | *********** ******** *********** ****** ** ****** ********** | ******* *** *** *********** ** *-[*-(*,*-********-******)-**-*******-*-**]-*-(*-******-*********-*-**)-*-(**********-*****-*-*******)-********* | *********** ******** *********** ****** ** ****** ********** | *********** ******** *********** ****** ** ****** ********** | ********* ** ******** ******* ************** ** *-[*-(*,*-********-******)-**-*******-*-**]-*-(*-******-*********-*-**)-*-(**********-*****-*-*******)-********* | ********* *** ************** ** **** ****** ****** ***** | ************** ************ *** ****** ***** | ******* *** ******** ************* | *********** **** ** *-[*-(*,*-********-******)-**-*******-*-**]-*-(*-******-*********-*-**)-*-(**********-*****-*-*******)-********* | *********** **** ** *-[*-(*,*-********-******)-**-*******-*-**]-*-(*-******-*********-*-**)-*-(**********-*****-*-*******)-********* | ************** ************ *** ****** ***** |
Download ParaIV Report
| Drug Name | Generic Name | Dosage | Route of Administration | Probable FTF | Known Para IV Filers | Other ANDA Developers |
|---|